Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Receptor, ErbB-2"" wg kryterium: Temat


Tytuł:
Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.
Autorzy:
Chui MH; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brown DN; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Da Cruz Paula A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
da Silva EM; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Momeni-Boroujeni A; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Reis-Filho JS; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zhang Y; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Makker V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ellenson LH; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weigelt B; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło:
The Journal of pathology [J Pathol] 2024 Feb; Vol. 262 (2), pp. 129-136. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Endometrial Neoplasms*/drug therapy
Endometrial Neoplasms*/genetics
Endometrial Neoplasms*/pathology
Female ; Humans ; In Situ Hybridization, Fluorescence ; Neoplasm Recurrence, Local/genetics ; Trastuzumab/therapeutic use ; Gene Amplification
Czasopismo naukowe
Tytuł:
Radiolabelled Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers.
Autorzy:
Cieslik PA; University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Klingler S; University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Nolff M; Klinik für Kleintierchirurgie, Vetsuisse-Fakultät, University of Zurich, Wintherturerstrasse 260, CH-8057, Zurich, Switzerland.
Holland JP; University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Pokaż więcej
Źródło:
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2024 Mar 07; Vol. 30 (14), pp. e202303805. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Radioisotopes*
Neoplasms*/diagnostic imaging
Neoplasms*/drug therapy
Receptor, ErbB-2*
Bridged Bicyclo Compounds, Heterocyclic*
Animals ; Mice ; Humans ; Female ; Trastuzumab ; Mice, Nude ; Ligands ; Cell Line, Tumor ; Lutetium
Czasopismo naukowe
Tytuł:
Clinical significance of CD166 and HER-2 in different types of gastric cancer.
Autorzy:
Moradi L; Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Tajik F; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Saeednejad Zanjani L; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Pathology and Genomic Medicine, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Panahi M; Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Gheytanchi E; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Biabanaki ZS; Faculty of Biological Sciences, Department of Genetics, Tarbiat Modares University, Tehran, Iran.
Kazemi-Sefat GE; Faculty of Advanced Technologies in Medicine, Department of Molecular Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hashemi F; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.; Faculty of Advanced Technologies in Medicine, Department of Molecular Medicine, Iran University of Medical Sciences, Tehran, Iran.
Dehghan Manshadi M; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.; Faculty of Advanced Technologies in Medicine, Department of Molecular Medicine, Iran University of Medical Sciences, Tehran, Iran.
Madjd Z; Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. .; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. .; Faculty of Advanced Technologies in Medicine, Department of Molecular Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Pokaż więcej
Źródło:
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Mar; Vol. 26 (3), pp. 664-681. Date of Electronic Publication: 2023 Aug 03.
Typ publikacji:
Journal Article
MeSH Terms:
Clinical Relevance*
Stomach Neoplasms*/pathology
Receptor, ErbB-2*
Humans ; Biomarkers, Tumor/metabolism ; Prospective Studies ; Prognosis
Czasopismo naukowe
Tytuł:
ASO Visual Abstract: Are There more HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity by Using Fluorescent In Situ Hybridization in Patients with HER2-Negative Immunohistochemistry.
Autorzy:
Suydam C; Department of Surgery, Eisenhower Army Medical Center, Augusta, USA. .
Chibane F; Department of Surgery, Medical College of Georgia at Augusta University Health, Augusta, USA.
Brown N; Department of Surgery, Medical College of Georgia at Augusta University Health, Augusta, USA.
Schlafly M; Department of Surgery, Medical College of Georgia at Augusta University Health, Augusta, USA.
Arnold AH; Department of Surgery, Medical College of Georgia at Augusta University Health, Augusta, USA.
Ghleilib I; Department of Pathology, Medical College of Georgia at Augusta University Health, Augusta, USA.
Easley M; Department of Surgery, Medical College of Georgia at Augusta University Health, Augusta, USA.
White J; Department of Pathology, Medical College of Georgia at Augusta University Health, Augusta, USA.
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2024 Mar; Vol. 31 (3), pp. 1660.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/genetics
Biomarkers, Tumor*
Humans ; In Situ Hybridization, Fluorescence ; Immunohistochemistry ; Patients
Czasopismo naukowe
Tytuł:
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis.
Autorzy:
Michelon I; Department of Medicine, Catholic University of Pelotas, Pelotas, Brazil.
Vilbert M; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA. Electronic address: .
Marinho AD; Department of Medicine, Federal University of the State of Rio de Janeiro, Rio de Janeiro.
Castro CER; Department of Medicine, University of Brasilia, Brasilia.
Dacoregio MI; Department of Medicine, University of Centro Oeste, Guarapuava.
Stecca C; Department of Medicine, Parana Oncology Center, Curitiba.
Soares LR; Department of Medicine, Federal University of Goiás, Goiania, Brazil.
Batista MV; Medical Oncology Department, Hospital Prof. Doctor Fernando Fonseca, Amadora; Haematology and Oncology Department, CUF Oncology, Sintra, Portugal.
Braga S; Medical Oncology Department, Hospital Prof. Doctor Fernando Fonseca, Amadora; Haematology and Oncology Department, CUF Oncology, Sintra, Portugal.
Saeed A; Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh.
Cavalcante L; Department of Medical Oncology and Hematology, University of Virginia Comprehensive Cancer Center, Charlottesville, USA. Electronic address: .
Pokaż więcej
Źródło:
ESMO open [ESMO Open] 2024 Feb; Vol. 9 (2), pp. 102233. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Brain Neoplasms*/drug therapy
Receptor, ErbB-2*
Immunoconjugates*
Camptothecin/*analogs & derivatives
Humans ; Female ; Trastuzumab/pharmacology ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł:
Design, synthesis and bioactivity evaluation of novel fusion peptides and their CPT conjugates inducing effective anti-tumor responses on HER2 positive tumors.
Autorzy:
Zhou J; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Xie Z; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Wang J; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Zeng Z; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Hu Z; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Zhong L; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Yang Q; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China.
Shi W; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China. Electronic address: .
Qian H; Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China; Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, PR China. Electronic address: .
Pokaż więcej
Źródło:
European journal of medicinal chemistry [Eur J Med Chem] 2024 Jan 15; Vol. 264, pp. 116032. Date of Electronic Publication: 2023 Dec 07.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/metabolism
Caspases*/metabolism
Humans ; Cell Death ; Peptides/pharmacology ; Antibodies, Monoclonal ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.
Autorzy:
Singh H; Division of Gastrointestinal Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Kang A; Curta, Seattle, WA, USA.
Bloudek L; Curta, Seattle, WA, USA.
Hsu LI; Seagen Inc., Bothell, WA, USA.
Corinna Palanca-Wessels M; Seagen Inc., Bothell, WA, USA.
Stecher M; Seagen Inc., Bothell, WA, USA.
Siadak M; Seagen Inc., Bothell, WA, USA.
Ng K; Division of Gastrointestinal Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.
Pokaż więcej
Źródło:
JNCI cancer spectrum [JNCI Cancer Spectr] 2024 Jan 04; Vol. 8 (1).
Typ publikacji:
Systematic Review; Meta-Analysis; Journal Article
MeSH Terms:
Receptor, ErbB-2*/genetics
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/drug therapy
United States ; Humans ; Biomarkers, Tumor/genetics ; Treatment Outcome ; Immunohistochemistry
Czasopismo naukowe
Tytuł:
Direct competitive assay for HER2 detection in human plasma using Bloch surface wave-based biosensors.
Autorzy:
Pileri T; SAPIENZA Università di Roma, Department of Basic and Applied Sciences for Engineering, Via A. Scarpa, 16, 00161, Roma, Italy.
Sinibaldi A; SAPIENZA Università di Roma, Department of Basic and Applied Sciences for Engineering, Via A. Scarpa, 16, 00161, Roma, Italy; Center for Life Nano and Neuro Science, Italian Institute of Technology (IIT), Viale Regina Elena 291, 00161, Rome, Italy. Electronic address: .
Occhicone A; SAPIENZA Università di Roma, Department of Basic and Applied Sciences for Engineering, Via A. Scarpa, 16, 00161, Roma, Italy; Center for Life Nano and Neuro Science, Italian Institute of Technology (IIT), Viale Regina Elena 291, 00161, Rome, Italy.
Danz N; Fraunhofer Institute for Applied Optics and Precision Engineering, A.-Einstein-Str. 7, 07745, Jena, Germany.
Giordani E; Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Allegretti M; Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Sonntag F; Fraunhofer Institute for Material and Beam Technology IWS, Winterbergstr. 28, 01277, Dresden, Germany.
Munzert P; Fraunhofer Institute for Applied Optics and Precision Engineering, A.-Einstein-Str. 7, 07745, Jena, Germany.
Giacomini P; Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Michelotti F; SAPIENZA Università di Roma, Department of Basic and Applied Sciences for Engineering, Via A. Scarpa, 16, 00161, Roma, Italy; Center for Life Nano and Neuro Science, Italian Institute of Technology (IIT), Viale Regina Elena 291, 00161, Rome, Italy.
Pokaż więcej
Źródło:
Analytical biochemistry [Anal Biochem] 2024 Jan 01; Vol. 684, pp. 115374. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Biosensing Techniques*
Receptor, ErbB-2*/blood
Humans ; Fluorescence ; Antibodies, Monoclonal/chemistry ; Lab-On-A-Chip Devices ; Protein Array Analysis
Czasopismo naukowe
Tytuł:
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Autorzy:
Ivanova M; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Porta FM; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
D'Ercole M; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Pescia C; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Sajjadi E; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.
Cursano G; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
De Camilli E; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Pala O; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Mazzarol G; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Venetis K; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Guerini-Rocco E; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.
Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.; Division of New Drugs and Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, 20141, Milan, Italy.
Viale G; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Fusco N; Division of Pathology, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy. .; Department of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy. .
Pokaż więcej
Źródło:
Virchows Archiv : an international journal of pathology [Virchows Arch] 2024 Jan; Vol. 484 (1), pp. 3-14. Date of Electronic Publication: 2023 Sep 28.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Receptor, ErbB-2*/genetics
Breast Neoplasms*/metabolism
Humans ; Female ; In Situ Hybridization, Fluorescence/methods ; Artificial Intelligence ; In Situ Hybridization ; Biomarkers, Tumor
Czasopismo naukowe
Tytuł:
Are There More HER2 FISH in the Sea? An Institution's Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry.
Autorzy:
Suydam C; Department of Surgery, Eisenhower Army Medical Center, Fort Gordon, GA, USA. .
Chibane F; Department of Surgery, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
Brown N; Department of Surgery, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
Schlafly M; Department of Surgery, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
Arnold AH; Department of Surgery, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
Ghleilib I; Department of Pathology, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
Easley M; Department of Surgery, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
White J; Department of Pathology, Medical College of Georgia at Augusta Health, Augusta, GA, USA.
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2024 Jan; Vol. 31 (1), pp. 376-381. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/genetics
Breast Neoplasms*/diagnosis
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Humans ; Female ; Biomarkers, Tumor ; Retrospective Studies ; In Situ Hybridization, Fluorescence/methods ; Immunohistochemistry
Czasopismo naukowe
Tytuł:
ASO Visual Abstract: Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?
Autorzy:
Polidorio N; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Montagna G; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sevilimedu V; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Le T; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Morrow M; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2024 Apr; Vol. 31 (4), pp. 2282.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/genetics
Neoplasms*
Humans ; Phenotype
Czasopismo naukowe
Tytuł:
Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?
Autorzy:
Polidorio N; Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Montagna G; Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sevilimedu V; Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Le T; Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Morrow M; Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2024 Apr; Vol. 31 (4), pp. 2231-2243. Date of Electronic Publication: 2023 Dec 29.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/metabolism
Breast Neoplasms*/genetics
Breast Neoplasms*/surgery
Breast Neoplasms*/metabolism
Humans ; Female ; In Situ Hybridization, Fluorescence ; Receptors, Estrogen/metabolism ; Phenotype
Czasopismo naukowe
Tytuł:
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Autorzy:
Seo J; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.
Koh J; Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
Lee DW; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. .; Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. .; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. .
Kim J; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Ryu HS; Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
Lee KH; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Kim TY; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
Im SA; Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. .; Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. .; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. .; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. .
Pokaż więcej
Źródło:
Breast cancer research : BCR [Breast Cancer Res] 2023 Dec 14; Vol. 25 (1), pp. 154. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Humans ; Female ; Trastuzumab/therapeutic use ; Docetaxel ; Retrospective Studies ; In Situ Hybridization ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
Autorzy:
Chen Z; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.; Department of Pathology, School of Basic Medicine, Qingdao University, Qingdao, 266021, Shandong, China.
Jia H; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.
Zhang H; Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14624, USA.
Chen L; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.; Department of Pathology, School of Basic Medicine, Qingdao University, Qingdao, 266021, Shandong, China.
Zhao P; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.
Zhao J; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.
Fu G; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.
Xing X; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.
Li Y; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China.
Wang C; Department of Pathology, The Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, 266000, Shandong, China. .; Department of Pathology, School of Basic Medicine, Qingdao University, Qingdao, 266021, Shandong, China. .
Pokaż więcej
Źródło:
Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Nov; Vol. 202 (2), pp. 313-323. Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Receptor, ErbB-2*/biosynthesis
Receptor, ErbB-2*/genetics
Female ; Humans ; Asian People ; Disease-Free Survival ; Multivariate Analysis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Autorzy:
Le Du F; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
Carton M; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
Bachelot T; Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.
Saghatchian M; Department of Medical Oncology, Hôpital Américain, Paris, France.
Pistilli B; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
Brain E; Department of Medical Oncology, Institut Curie/Saint Cloud, Paris, France.
Loirat D; Department of Biostatistics, Institut Curie, Saint-Cloud, France.
Vanlemmens L; Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
Vermeulin T; Centre Henri Becquerel, Rouen, France.
Emile G; Department of Medical Oncology, Centre François Baclesse, Caen, France.
Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Ung M; Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France.
Robert M; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France.
Jaffre A; Anne jaffré Department of Medical Information, Institut Bergonié, Bordeaux, France.
Desmoulins I; Department of Medical Oncology, Centre Jean-Francois Leclerc, Dijon, France.
Jouannaud C; Department of Medical Oncology, Institut Godinot, Reims, France.
Uwer L; Institut de Cancérologie de Lorraine, Nancy, France.
Marc Ferrero J; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
Mouret-Reynier MA; Department of Medical Oncology, Clermont-Ferrand, France.
Jacot W; Department of Medical Oncology, Institut du cancer de Montpellier, Montpellier, France.
Chevrot M; Health Data and Partnership Department, Unicancer, Paris, France.
Delaloge S; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
Diéras V; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2023 Oct 03; Vol. 28 (10), pp. e867-e876.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Trastuzumab*/therapeutic use
Chemotherapy, Adjuvant*
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols ; Disease-Free Survival ; Progression-Free Survival
Czasopismo naukowe
Tytuł:
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.
Autorzy:
Liu B; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Xie N; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Tian C; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Feng R; Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, Hunan, 415000, China.
Hu ZY; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Li J; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Liu L; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Xiao H; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Yang X; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Zeng M; Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, Hunan, 415000, China.
Wu H; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Lu J; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Gao J; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Hu X; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Cao M; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Shui Z; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Tang Y; Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China.
Wu T; Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University, Changde, Hunan, 415000, China. Electronic address: .
Ouyang Q; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China. Electronic address: .
Pokaż więcej
Źródło:
Breast (Edinburgh, Scotland) [Breast] 2023 Dec; Vol. 72, pp. 103597. Date of Electronic Publication: 2023 Nov 01.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/secondary
Receptor, ErbB-2*/antagonists & inhibitors
Antibodies, Monoclonal*/therapeutic use
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; East Asian People ; Trastuzumab/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors.
Autorzy:
Feldman D; Faculty of Medicine, The Technion Institute of Technology, Haifa, Israel.
Sinberger LA; Department of Molecular Biology, Ariel University, Ariel, Israel.
Salmon-Divon M; Department of Molecular Biology, Ariel University, Ariel, Israel.; Adelson School of Medicine, Ariel University, Ariel, Israel.
Ben-Dror J; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Shachar SS; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.; School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sonnenblick A; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. .; School of Medicine, Tel Aviv University, Tel Aviv, Israel. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Oct 24; Vol. 23 (1), pp. 1031. Date of Electronic Publication: 2023 Oct 24.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/metabolism
Breast Neoplasms*/pathology
Humans ; Female ; RNA ; Retrospective Studies ; Immunohistochemistry ; Polymerase Chain Reaction
Czasopismo naukowe
Tytuł:
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
Autorzy:
Lin HK; Department of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA.
Can T; Exact Sciences Corporation, Redwood City, CA, USA.
Kahn A; Department of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA.
Flannery CA; Exact Sciences Corporation, Redwood City, CA, USA.
Hoag J; Exact Sciences Corporation, Redwood City, CA, USA.
Akkunuri A; Exact Sciences Corporation, Redwood City, CA, USA.
Bailey H; Exact Sciences Corporation, Redwood City, CA, USA.
Baehner R; Exact Sciences Corporation, Redwood City, CA, USA.
Pusztai L; Department of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA.
Rozenblit M; Department of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2023 Oct 03; Vol. 28 (10), pp. e973-e976.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Receptor, ErbB-2*/genetics
Breast Neoplasms*/genetics
Breast Neoplasms*/pathology
Humans ; Female ; Reverse Transcriptase Polymerase Chain Reaction ; Reproducibility of Results ; Receptors, Estrogen/genetics ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/analysis ; Prognosis
Czasopismo naukowe
Tytuł:
HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Autorzy:
Edjtemaei R; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Nili F; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: .
Jahanzad I; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ameli F; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ghasemi D; Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
Annals of diagnostic pathology [Ann Diagn Pathol] 2023 Oct; Vol. 66, pp. 152184. Date of Electronic Publication: 2023 Jul 26.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Carcinoma*
Cystadenocarcinoma, Serous*/diagnosis
Endometrial Neoplasms*/metabolism
Receptor, ErbB-2*/metabolism
Female ; Humans ; Biomarkers, Tumor/analysis ; Endometrium/pathology ; In Situ Hybridization, Fluorescence/methods ; Prognosis
Czasopismo naukowe
Tytuł:
Contribution of PGAP3 co-amplified and co-overexpressed with ERBB2 at 17q12 involved poor prognosis in gastric cancer.
Autorzy:
Wang D; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Hao S; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
He H; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhang J; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
You G; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wu X; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhang R; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Meng X; Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China.
Cui X; Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China.
Bai J; Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China.
Fu S; Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China.
Yu J; Scientific Research Centre, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.; Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China (Harbin Medical University), Ministry of Education, Harbin, China.
Pokaż więcej
Źródło:
Journal of cellular and molecular medicine [J Cell Mol Med] 2023 Aug; Vol. 27 (16), pp. 2424-2436. Date of Electronic Publication: 2023 Jun 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Stomach Neoplasms*/pathology
Humans ; Cell Line, Tumor ; Cell Proliferation/genetics ; Carboxylic Ester Hydrolases ; Receptors, Cell Surface
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies